-20C

Cell Signaling EphA1 (D6V7I) Rabbit mAb H. Orders: Support:



-



3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 130	Source/Isotype: Rabbit IgG	UniProt ID: #P21709	Entrez-Gene Id: 2041	
Product Usage Information		Application Western Blotting			Dilution 1:1000		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.					
Specificity/Sensitivity		EphA1 (D6V7I) Rabbit mAb recognizes endogenous levels of total EphA1 protein.					
Source / Purification		Monoclonal antibody is produced by immunizing animals with a recombinant protein fragment specific to the extracellular domain of human EphA1 protein.					
Background		The Eph receptors are into two groups based EphA receptors bind to to ephrin B proteins th shown that Eph recept ephrin A and B ligands receptors and activate is sufficient for this fur described as "reverse allowing interactions w cells (5). The EphA1 receptor pr stimulates EphA1 sign pathway (7). The <i>EphA</i> EphA1 in cancer devel prostate, gastric and li invasion (10-12). For o downregulation of the modulation of Ephrin-	the largest known on sequence simil of a glycosylphospha tat have a transment cors and ligands may a have dual function signaling pathway nction as long as it signaling", whereby with other proteins referentially binds effect aling and regulates of gene has been as opment falls into two ver cancer, high exit ther types of cance of protein correlates Ephrin receptor into	family of receptor tyrosin arity and on their prefere atidylinositol-anchored e nbrane and cytoplasmic by be involved in many di s. As RTK ligands, ephrin s in receptor-expressing is clustered (4). The secon the cytoplasmic domain that may activate signali ephrin-A1 as a ligand (6). cell morphology and ma sociated with late-onset to opposite categories. I pression of EphA1 associ rs, such as colon cancer with cancer development eraction might contribute	ne kinases (RTKs). 1 ence for a subset o phrin A ligand, Eph domain (1,2). Rese iseases including c ns stimulate the kir cells. The ephrin e nd function of eph n becomes tyrosine ng pathways in the This ligand-recepto otility through the Alzheimer's diseas n some type of can ates with cancer m and nonmelanoma it (11,12). The bidir e this paradox phe	They can be divided f ligands. While be receptors bind earch studies have ancer (3). Both hase activity of Eph xtracellular domain rins has been e phosphorylated, e ligand-expressing or interaction ILK-RhoA-ROCK ses (8,9). The role of focer such as netastasis and a skin cancer, ectional signaling nomena (13).	
Background Re	ferences	1. Wilkinson, D.G. (200 2. Klein, R. (2001) <i>Curr</i> 3. Dodelet, V.C. and Pa 4. Holder, N. and Klein 5. Brückner, K. et al. (1 6. Coulthard, M.G. et a 7. Yamazaki, T. et al. (2 8. Naj, A.C. et al. (2011 9. Hollingworth, P. et a 10. Wang, Y. et al. (201 11. Herath, N.I. et al. (201 12. Hafner, C. et al. (200 13. Pasquale, E.B. (200	0) <i>Int Rev Cytol</i> 196 <i>Opin Cell Biol</i> 13, 1 Isquale, E.B. (2000) , R. (1999) <i>Developi</i> 997) <i>Science</i> 275, 1 I. (2001) <i>Growth Fa</i> 009) <i>J Cell Sci</i> 122, 2) <i>Nat Genet</i> 43, 436 il. (2011) <i>Nat Genet</i> 6) <i>J Exp Clin Cancer</i> 2009) <i>Br J Cancer</i> 10 06) <i>Mod Pathol</i> 19, 8) <i>Cell</i> 133, 38-52.	, 177-244. 96-203. <i>Oncogene</i> 19, 5614-9. <i>ment</i> 126, 2033-44. 640-3. <i>ctors</i> 18, 303-17. 243-55. -41. 43, 429-35. <i>rRes</i> 35, 65. 00, 1095-102. 1369-77.			
Species Reactiv	ity	Species reactivity is de	termined by testing	g in at least one approve	d application (e.g.,	western blot).	
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.					
Applications Ke	У	W: Western Blotting					

Cross-Reactivity Key	H: Human M: Mouse
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purpose, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.